Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2CNS 2

Conditions

Neoplasms 17Carcinoma 5Neoplasm Metastasis 3Colonic Neoplasms 3Brain Neoplasms 3Prostatic Neoplasms 2Peritoneal Neoplasms 2Ovarian Neoplasms 2Lung Neoplasms 2Fallopian Tube Neoplasms 2Colorectal Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Breast Neoplasms 2Vipoma 1Recurrence 1Neuroendocrine Tumors 1Meningeal Carcinomatosis 1Melanoma 1Liver Neoplasms 1Kidney Neoplasms 1Hormone Refractory Prostate Cancer 1Head and Neck Neoplasms 1Glioblastoma 1Gastrinoma 1Central Nervous System Neoplasms 1Carcinoma, Ovarian Epithelial 1Carcinoma, Hepatocellular 1Carcinoid Tumor 1Breast Neoplasms, Male 1Advanced Malignancies 1

Interventions

Carboplatin 345Cisplatin 240Paclitaxel 208Radiotherapy 206Pemetrexed 190Docetaxel 170Gemcitabine 158pembrolizumab 146Erlotinib Hydrochloride 111Magnetic Resonance Spectroscopy 101Etoposide 98Bevacizumab 96Specimen Handling 84Nivolumab 77durvalumab 73Radiosurgery 73Blood Specimen Collection 65Drug Therapy 61osimertinib 56Vinorelbine 54Gefitinib 50Surveys and Questionnaires 48atezolizumab 44Biopsy 43Irinotecan 42Radiation 41Topotecan 39Standard of Care 38Cyclophosphamide 38Surgical Procedures, Operative 35

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Lung Neoplasms × epothilone B × Clear all
NCT00219297 2021-02-21

Study of Patupilone in Patients With Brain Metastasis From Non-small Cell Lung Cancer

Novartis

Phase 2 Completed
50 enrolled
CNSThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT00171834 2014-02-05

Dose Escalating Study of the Safety and Efficacy of Patupilone, q3w, in Patients With Non-small Cell Lung Cancer

Novartis

Phase 1/2 Completed
89 enrolled 20 charts
CNSThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡